Hypothesis

Core proposition: NAD+ depletion in aging vocal folds is not a primary driver of tissue degeneration but a compensatory metabolic brake that limits energy‑expensive biosynthetic programs in senescent fibroblasts, thereby restraining matrix synthesis while allowing controlled proteolytic remodeling.

Mechanistic Rationale

1. Senescence‑associated DNA damage in vocal fold thyroarytenoid fibroblasts activates PARP1, consuming NAD+ faster than NAMPT can replenish it (1).
2. Falling NAD+ reduces SIRT1 activity, leading to hyper‑acetylation of FOXO1 and PGC‑1α, which shifts transcription toward MMP‑9 and MMP‑13 expression and away from COL1A1/ELN synthesis (2).
3. The resulting ECM phenotype—decreased collagen/elastin deposition and increased proteolytic turnover—matches the lamina propria disorganization seen in presbyphonia (4).
4. Because NAD+ loss curtails ATP‑intensive collagen cross‑linking, the tissue avoids excessive stiffening that could impair vibration; instead, it maintains a more compliant, albeit weaker, matrix that preserves basic phonatory function at the cost of vocal endurance.

Testable Predictions

• Prediction 1: In aged mouse vocal folds, pharmacological inhibition of CD38 (to raise NAD+) will increase SIRT1 activity but will not reduce MMP activity unless senescent fibroblasts are concurrently cleared.
• Prediction 2: Combining NAD+ precursors (e.g., NR) with a senolytic (e.g., dasatinib + quercetin) will lower MMP‑9/13 levels, increase collagen deposition, and improve high‑frequency vocal fold vibration metrics compared with NAD+ boosting alone.
• Prediction 3: Fibroblast‑specific overexpression of PARP1 will recapitulate NAD+ drop, SIRT1 inhibition, and the MMP‑rich ECM signature even in young animals, confirming causality.

Experimental Approach

• Use aged (24‑month) C57BL/6 mice and isolate vocal fold fibroblasts.
• Treat groups: (a) vehicle, (b) NR (NAD+ precursor), (c) dasatinib+quercetin (senolytic), (d) NR+senolytic.
• Measure NAD+ levels, SIRT1 activity, acetyl‑FOXO1, MMP‑9/13, COL1A1, ELN by qPCR/Western blot.
• Assess ECM composition via hydroxyproline assay and immunofluorescence.
• Ex vivo vocal fold vibration testing using high‑speed imaging to obtain fundamental frequency and strain.
• Statistical analysis via two‑way ANOVA with post‑hoc Tukey.

Potential Outcomes & Interpretation

• If NR alone raises NAD+ but does not decrease MMPs or improve vibration, while the combination does, this supports the hypothesis that NAD+ decline is a protective brake whose removal without senescent cell clearance exacerbates maladaptive remodeling.
• Conversely, if NR monotherapy reduces MMPs and enhances vibration, the hypothesis would be falsified, indicating NAD+ loss is pathogenic rather than adaptive.

Broader Implications

Reframing NAD+ as a metabolic checkpoint could explain why NAD+‑boosting trials show mixed results in age‑related diseases and suggest that senolysis must precede or accompany NAD+ augmentation in vocal fold rejuvenation strategies.